Clinical Trials Directory

Emergency Use Protocol for EPI-743 in Acutely Ill Patients With Inherited Mitochondrial Respiratory Chain Disease Within 90 Days of End-of-Life Care

This study evaluates the safety and efficacy of EPI-743 in patients with severe mitochondrial respiratory chain diseases who are considered to be within 90 days of end-of-life care.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : EPI-743

Phase: Phase 2


Ages Eligible For Study:

1 Year - N/A

External Links

Explore related trials

Contact information

Primary Contact:

Greg Enns, MD (650) 498-5798

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: